Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Orforglipron is currently in late-stage testing for type 2 diabetes, obesity and obstructive sleep apnea. Unlike Lilly’s injectable GLP-1 currently on the market, tirzepatide, orforglipron is an ...

I'm talking about weight loss drugs. Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. But doctors have prescribed either one for ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs.

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...

Data in diabetes suggests tirzepatide could be a disruptive force in the diabetes market, as Lilly tries to position it as a replacement for its $5 billion once-weekly GLP-1 drug Trulicity ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

president of Eli Lilly diabetes and obesity, in an interview. Medicare beneficiaries are also not eligible for Eli Lilly's savings card programs for Zepbound. Jonsson said "in an ideal world," the ...